These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39027879)

  • 1. Non-vitamin K oral antagonist (NOAC) compared to vitamin K antagonist (VKA) in left ventricular thrombus.
    Al-Kaf F; Al Basiri S; Al Ash'hab Y; Otain M; Al Askary H; Khushail AA; Robert AA; Al Fagih A
    J Family Med Prim Care; 2024 Jun; 13(6):2485-2490. PubMed ID: 39027879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction.
    Jones DA; Wright P; Alizadeh MA; Fhadil S; Rathod KS; Guttmann O; Knight C; Timmis A; Baumbach A; Wragg A; Mathur A; Antoniou S
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):398-404. PubMed ID: 32730627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban versus Vitamin K Antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction.
    Zhang Z; Si D; Zhang Q; Qu M; Yu M; Jiang Z; Li D; Yang P; Zhang W
    Heart Vessels; 2022 Mar; 37(3):374-384. PubMed ID: 34420077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
    De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
    J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus.
    Huang L; Tan Y; Pan Y
    ESC Heart Fail; 2022 Oct; 9(5):3519-3532. PubMed ID: 35894752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries.
    Russo V; Attena E; Baroni M; Trotta R; Manu MC; Kirchhof P; De Caterina R
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ventricular thrombus: An updated meta-analysis.
    Shrestha DB; Dawadi S; Dhakal B; Shtembari J; Patel T; Shaikh R; Bodziock GM; Shantha G; Trankle CR; Patel NK
    Health Sci Rep; 2023 Nov; 6(11):e1736. PubMed ID: 38028683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.
    Russo V; Bottino R; Rago A; Papa AA; Liccardo B; D'Onofrio A; Golino P; Nigro G
    Semin Thromb Hemost; 2020 Nov; 46(8):970-976. PubMed ID: 33105504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study.
    Tang L; Liu H; Deng H; Zhan X; Fang X; Liao H; Liu Y; Fu L; Fu Z; Liu H; Wu S; Xue Y
    Front Med (Lausanne); 2020; 7():197. PubMed ID: 32582721
    [No Abstract]   [Full Text] [Related]  

  • 13. Vitamin K antagonist versus novel oral anticoagulants for management of cervical artery dissection: Interactive systematic review and meta-analysis.
    Essibayi MA; Lanzino G; Keser Z
    Eur Stroke J; 2022 Dec; 7(4):349-357. PubMed ID: 36478754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and hypertrophic cardiomyopathy].
    Liu YY; Du X; He L; Hu R; Ning M; Lyu J; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jan; 50(1):62-67. PubMed ID: 35045616
    [No Abstract]   [Full Text] [Related]  

  • 15. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.
    Bellin A; Berto P; Themistoclakis S; Chandak A; Giusti P; Cavalli G; Bakshi S; Tessarin M; Deambrosis P; Chinellato A
    PLoS One; 2019; 14(10):e0222762. PubMed ID: 31589620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantation.
    Mangner N; Brinkert M; Keller LS; Moriyama N; Hagemeyer D; Haussig S; Crusius L; Kobza R; Abdel-Wahab M; Laine M; Stortecky S; Pilgrim T; Nietlispach F; Ruschitzka F; Thiele H; Toggweiler S; Linke A
    EuroIntervention; 2023 Feb; 18(13):e1066-e1076. PubMed ID: 36440479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable safety profile of NOAC therapy in patients after tricuspid transcatheter edge-to-edge repair.
    Hoerbrand IA; Kraus MJ; Gruber M; Geis NA; Schlegel P; Frey N; Konstandin MH
    Clin Res Cardiol; 2024 Aug; ():. PubMed ID: 39158599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial.
    Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ
    BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.